WO2024089179A1 - Dairy lipid for lowering the glycoprotein acetyls (glyca) - Google Patents
Dairy lipid for lowering the glycoprotein acetyls (glyca) Download PDFInfo
- Publication number
- WO2024089179A1 WO2024089179A1 PCT/EP2023/079941 EP2023079941W WO2024089179A1 WO 2024089179 A1 WO2024089179 A1 WO 2024089179A1 EP 2023079941 W EP2023079941 W EP 2023079941W WO 2024089179 A1 WO2024089179 A1 WO 2024089179A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipid
- lipid fraction
- composition
- glyca
- subject
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title claims abstract description 180
- 235000013365 dairy product Nutrition 0.000 title claims abstract description 49
- 102000003886 Glycoproteins Human genes 0.000 title claims description 8
- 108090000288 Glycoproteins Proteins 0.000 title claims description 8
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 claims description 78
- 230000000291 postprandial effect Effects 0.000 claims description 51
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 49
- 239000000194 fatty acid Substances 0.000 claims description 49
- 229930195729 fatty acid Natural products 0.000 claims description 49
- 150000004665 fatty acids Chemical class 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 37
- 239000006071 cream Substances 0.000 claims description 26
- 235000021243 milk fat Nutrition 0.000 claims description 26
- 206010061218 Inflammation Diseases 0.000 claims description 25
- 230000004054 inflammatory process Effects 0.000 claims description 25
- KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 claims description 22
- 230000009467 reduction Effects 0.000 claims description 20
- 239000000047 product Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 10
- 239000008158 vegetable oil Substances 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 9
- 235000008939 whole milk Nutrition 0.000 claims description 9
- 235000016709 nutrition Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 230000035764 nutrition Effects 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 235000021125 infant nutrition Nutrition 0.000 claims description 2
- 235000014268 sports nutrition Nutrition 0.000 claims description 2
- 101710191666 Lactadherin Proteins 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 239000003925 fat Substances 0.000 description 29
- 235000019197 fats Nutrition 0.000 description 26
- 239000002207 metabolite Substances 0.000 description 20
- 235000013336 milk Nutrition 0.000 description 20
- 239000008267 milk Substances 0.000 description 20
- 210000004080 milk Anatomy 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 208000035475 disorder Diseases 0.000 description 16
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 241000283690 Bos taurus Species 0.000 description 9
- WQEPLUUGTLDZJY-UHFFFAOYSA-N pentadecanoic acid Chemical compound CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 8
- 230000001550 time effect Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 235000012239 silicon dioxide Nutrition 0.000 description 6
- 235000019871 vegetable fat Nutrition 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000014171 Milk Proteins Human genes 0.000 description 4
- 108010011756 Milk Proteins Proteins 0.000 description 4
- 241000282849 Ruminantia Species 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002705 metabolomic analysis Methods 0.000 description 4
- 230000001431 metabolomic effect Effects 0.000 description 4
- 235000021239 milk protein Nutrition 0.000 description 4
- 238000010149 post-hoc-test Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 3
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 235000019484 Rapeseed oil Nutrition 0.000 description 3
- 235000019486 Sunflower oil Nutrition 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 229940071162 caseinate Drugs 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 239000012628 flowing agent Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000019832 sodium triphosphate Nutrition 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 239000001226 triphosphate Substances 0.000 description 3
- 101001024942 Bos taurus Glucose-6-phosphate isomerase Proteins 0.000 description 2
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000502522 Luscinia megarhynchos Species 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000003346 palm kernel oil Substances 0.000 description 2
- 235000019865 palm kernel oil Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101001034318 Bos taurus Lactadherin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 241001661345 Moesziomyces antarcticus Species 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 229940040461 lipase Drugs 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 235000020806 vegan diet Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the invention disclosed herein relates to the use of dairy lipid to lower the GlycA level in a subject; to a composition comprising a lipid fraction for use in lowering the GlycA level in a subject.
- the invention further relates to a method for lowering the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject.
- the use, composition for use and the method additionally relate to reducing the risk of inflammation in a subject.
- Breast feeding is the best way to ensure healthy growth and development of infants during the first months of life. It is recommended by the WHO to exclusively provide breast feeding during the first six months of life and the introduction of safe and appropriate complementary feeding thereafter to supplement continued breast feeding up to two years of age or beyond. However, when mothers cannot or choose not to breastfeed for whatever reason a safe alternative to breast feeding is required, there is a legitimate role for breast milk substitutes, produced according to strict international compositional and safety standards.
- Glycoprotein acetyls is a unique inflammatory biomarker with analytic and clinical attributes that may complement or provide advantages over existing clinical markers of systemic inflammation. It is composed of a complex of heterogeneous NMR signal containing N-acetyl sugar groups originating from multiple acute-phase circulating glycoproteins.
- a simplified description how the GlycA ‘peak’ on NMR relates to systemic inflammation is given hereafter:
- macrophages are recruited to the site of inflammation where they secrete a variety of cytokines. These cytokines act locally to induce an inflammatory response aimed at removing the insulting trigger and promoting subsequent tissue recovery.
- cytokines also enter the systemic circulation and reach the liver, where they induce an increased production and secretion of several so-called acute phase reactants, as well as various glycosylation-mediating enzymes, known as glycosyltransferases, which alter the glycosylation patterns of the latter acute phase reactants.
- the acute phase reactants themselves, and their glycosyltransferase-modified derivatives contribute to the GlycA peak seen on the NMR spectrum (R.A. Bailout and A.T. Remaley J Lab Precis Med 2020;5:17 I http://dx.doi.org/10.21037/jlpm.2020.03.03). Accordingly, there is a need to keep the level of GlycA low in order to reduce the risk for inflammation.
- GlycA It was found that eating may result in an increase of the GlycA level. It is desired to have the GlycA levels return to their basal level as fast as possible in order to lower the risk of inflammation or any other condition related to increased levels of GlycA. It was surprisingly found that this so-called postprandial response is dependent on the diet being consumed. More surprisingly, it was found that GlycA returns faster to its basal level after consumption of milk fat as compared to consumption of vegetable fat.
- composition for use and method as defined in the claims. According to an aspect of the invention this is achieved by the features of claim 1.
- a use of dairy lipid to reduce the risk of inflammation in a subject and/or to lower the GlycA level in a subject; preferably, to lower the postprandial GlycA level in a subject.
- a composition comprising a lipid fraction for use in the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10 wt%.
- a method for reducing the risk of inflammation in a subject and/or to lower the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10 wt%.
- the invention relates to the use of a lipid fraction to lower the Glycoprotein acetyls (GlycA) level in a subject wherein the amount of C 15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- GlycA Glycoprotein acetyls
- the invention relates to the use of a lipid fraction to reduce the risk of inflammation in a subject and/or to lower the GlycA level in a subject wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the invention relates to the use of a lipid fraction to reduce the risk of inflammation in a subject and/or to lower the GlycA level in a subject wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids preferably is at least 0.20% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.12%; more preferably the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.30% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.18%.
- the amount of C15:0 in the lipid fraction is referring to amount of pentadecanoic acid that is esterified to the glycerol backbone, likewise, the amount of Cl 7:0 is referring to the amount of heptadecanoic acid that is esterified to the glycerol backbone.
- treatment in relation to a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder.
- prevention in relation to a given disease or disorder means preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
- a reduction of the risk of a disease or disorder means a lower likelihood that a given disease or disorder develops if none had occurred, and/or a lower likelihood that a given disease or disorder further develops if already present, and/or a lower likelihood that a given disease or disorder will be diagnosed.
- dairy lipid consists of dairy fat (i.e. milk fat) and dairy phospholipids (i.e. milk phospholipids). As such the total lipid fraction consists of dairy fat, vegetable fat, dairy phospholipid and vegetable phospholipid.
- the “dairy lipid” as used in this document may be obtained from milk of ruminants using methods known in the art, preferably from bovine milk fat, more preferably cow’s milk fat.
- the milk fat source can in principle be any available ruminant milk fat source, such as whole milk, cream, anhydrous milk fat (AMF) or milk fat fractions resulting from dry fractionation, critical CO2 extraction or other fractionation methods known in the art.
- the dairy lipid source can also be a source of milk fat globular membrane (MFGM).
- MFGM milk fat globular membrane
- the dairy lipid source can be a combination of different sources. It was, however, found particularly suitable to use whole milk, AMF, cream and/or MFGM as the dairy lipid source.
- the ruminant milk lipids are bovine milk lipids and the lipids are selected from the group consisting of anhydrous milk fat (AMF), cream, MFGM, and whole milk. More preferably, the lipids are selected from AMF, cream, or mixtures thereof. Even more preferably, the bovine milk lipids are cow milk lipids. In one embodiment the dairy lipid is bovine whole milk or cream.
- the dairy lipid is bovine whole milk, in another embodiment the dairy lipid is bovine cream, in still another embodiment the dairy lipid is bovine AMF.
- the dairy lipid source is bovine AMF and/or bovine MFGM.
- MFGM is referring to an MFGM enriched milk fraction. AMF and MFGM enriched milk fractions are readily commercially available from milk processing companies like FrieslandCampina, Aria, or Fonterra e.g. VMF100 (FrieslandCampina), Vivinal® MFGM (FrieslandCampina), Lacprodan® MFGM- 10 (Aria), SureStartTM MFGM Lipids (NZMP).
- milk lipid sources like whole milk, cream, anhydrous milk fat (AMF) or milk fat fractions resulting from dry fractionation, critical CO2 extraction or other fractionation methods.
- AMF anhydrous milk fat
- milk fat fractions resulting from dry fractionation, critical CO2 extraction or other fractionation methods are also readily commercially available.
- a thermization or pasteurization step is needed e.g. to meet legal requirements, this is possible using methods known in the art, for example at temperatures of about 63 °C (145 °F) maintained for 30 minutes or, heating to a higher temperature, e.g. 72 °C (162 °F), and holding for 15 seconds or, alternatively, e.g. an ultra-high temperature (UHT) treatment at not less than 135 °C in combination with a suitable holding time.
- UHT ultra-high temperature
- the ruminant milk lipids may be obtained from fresh milk.
- cream as used herein is referring to the fat portion from whole milk, preferably bovine milk. This fat portion may be separated from the whole milk using methods known in the art. Cream is comprising triglycerides and milk fat globular membrane (MFGM) fragments (such fragments may also be referred to as MFGM components).
- MFGM milk fat globular membrane
- the MFGM fragments comprise milk phospholipids and a large variety of (glyco)proteins.
- the milk fat globules comprise triglycerides surrounded with a membrane comprised of MFGM fragments.
- postprandial lipemia refers to a rise in circulating triglyceride- containing lipoproteins following consumption of a meal, postprandial lipemia has been recognized as a risk factor for the development of cardiovascular disease and other chronic diseases.
- the term "subject” as used herein preferably refers to a human.
- the term “subject” refers to both the male and female sex unless one sex is specifically indicated.
- the human subject can be an infant ( ⁇ 2 years old), a juvenile, an adolescent, an adult or an elderly subject.
- the human subject is aged 0-36 months.
- the human subject is aged 18 years and above, e.g. at least 25 years, at least 30 years, at least 35 years, at least 40 years, or at least 45 years. More preferably, the human subject is at least 50 years old, at least 55 years old, at least 60 years old or at least 65 years of age.
- human subjects treated in accordance with the invention will typically be at most 110 years of age, e.g. at most 100 or at most 90 years of age.
- the lowering of the GlycA level as referred to in the different aspects and/or embodiments of the invention is a reduction of the postprandial time needed for the GlycA level to start decreasing, preferably a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
- postprandial time is defined as the time after consumption of a consumption comprising a lipid fraction.
- the lipid fraction in the composition comprising a lipid fraction as referred to in the different aspects and/or embodiments of the invention comprises at least 10 wt% dairy lipid as determined to the total weight of lipid in the lipid fraction.
- the lowering of the GlycA level is one or more selected from the group consisting of i.
- a reduction in the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction as compared to the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of the same amount of vegetable oils is reduced with at least 5%, preferably at least 10%, more preferably at least 15% most preferably at least 20%; and/or ii. a decrease in the GlycA level in the subject between 5 and 6 hours post prandial, preferably between 4 and 6 hours post prandial, most preferably between 3 and 6 hours post prandial; and/or iii.
- the GlycA level being back at the basal level at 6 hours post prandial; and/or iv the GlycA level at 4.5 hours post prandial being at 60% or less of the GlycA level at 3 hours post prandial, preferably 50% or less; and /or v. the Area Under the Curve (AUG) of the delta postprandial response GlycA being reduced by at least 10%, preferably at least 20%.
- AUG Area Under the Curve
- the amount of dairy lipid as determined relative to the total weight of the lipid fraction in the composition comprising a lipid fraction as referred to in different embodiments and/or aspects of the current invention can be at least 20 wt%, preferably at least 30 wt%, more preferably at least 50 wt%, particularly preferably at least 75 wt%, most preferably at least 90wt%, such as at least 95 wt% or 99 wt%.
- the reduced risk of inflammation and/or the lowering of the GlycA level is preferably determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid. More preferably, the vegetable oils consist of a blend of palm olein oil, rapeseed oil low in erucic acid, palm kernel oil and sunflower oil.
- composition comprising a lipid fraction as referred to in different embodiments of the invention may be further comprising a carbohydrate fraction and a protein fraction; preferably wherein the composition comprising the lipid fraction is selected from the group consisting of infant nutrition product, adult nutrition product, a sports nutrition product, drink, candy, and a food supplement.
- infant nutrition product adult nutrition product
- sports nutrition product drink, candy, and a food supplement.
- dairy lipid may be increased in such products by replacing other sources of lipid, using methods known in the art.
- the invention in another aspect, relates to a composition
- a composition comprising a lipid fraction for use in lowering the GlycA level in a subject; wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the invention relates to a composition
- a composition comprising a lipid fraction for use in the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the invention relates to a composition comprising a lipid fraction for use in the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of Cl 7:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
- the invention may also be worded as the use of a composition comprising a lipid fraction in the manufacture of a medicament for use in lowering the GlycA level in a subject; wherein the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of Cl 7:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the invention relates to the use of such a composition comprising a lipid fraction in the manufacture of a medicament for use in the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the invention relates to a use of a composition comprising a lipid fraction for use in the manufacture of a medicament for the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
- the invention relates to a method for lowering the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the lowering of the GLycA level is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the invention relates to a method for reducing the risk of inflammation in a subject and/or to lower the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the invention relates to a method for reducing the risk of inflammation in a subject and/or to lower the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
- the lowering of the GlycA level is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
- the use, composition for use, and method of the invention as defined in the different aspects and embodiments of the invention relate to a reduction in the risk of inflammation in a subject and a lowering of the GlycA level in a subject.
- the invention relates to the use, the composition for use, or the method of the invention wherein the GlycA level is lowered and wherein the risk of inflammation is reduced; preferably wherein the reduced risk of inflammation is determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid.
- any reference to a weight, weight ratio, and the like pertains to the dry matter, in particular the dry matter of the composition.
- the term “essentially consisting of’ is a partially open term, which does not exclude additional, unrecited element(s), step(s), or in gre tower (s), as long as these additional element(s), step(s) or ingredient(s) do not materially affect the basic and novel properties of the invention.
- the term “comprising” hence includes the term “consisting of’ (“consist(s) of’), as well as the term “essentially consisting of’ (“essentially consist(s) of’). Accordingly, the term “comprising” (or “comprise(s)”) is, in the present application, meant as more particularly encompassing the term “consisting of’ (“consist(s) of’), and the term “essentially consisting of’ (“essentially consist(s) of’).
- percent, "parts of,” and ratio values are by weight; the description of a group or class of materials as suitable or preferred for a given purpose in connection with the invention implies that mixtures of any two or more of the members of the group or class are equally suitable or preferred; description of constituents in chemical terms refers to the constituents at the time of addition to any combination specified in the description, and does not necessarily preclude chemical interactions among the constituents of a mixture once mixed; the first definition of an acronym or other abbreviation applies to all subsequent uses herein of the same abbreviation and applies, mutatis mutandis, to normal grammatical variations of the initially defined abbreviation; and, unless expressly stated to the contrary, measurement of a property is determined by the same technique as previously or later referenced for the same property.
- FIG. 1 Differential effects of interventions on postprandial metabolites. Flowchart of A) the study design and B) the number of metabolites significantly changed in the interventions. Shake*time effect was tested using linear mixed models for repeated measures. Significant findings were corrected for multiple testing using FDR-correction (FDR p-value ⁇ 0.05). A LSD posthoc test was performed on metabolites with a significant FDR p-value for shake*time to identify differences between the shakes and shake*time effects at specific time points.
- the content of the different fatty acids in the lipid of the composition of the invention can be determined by standard method ISO 15884/IDF 182:2002 (Milk fat - Preparation of fatty acid methyl esters) and ISO 15885/IDF 184 (Milk fat - Determination of the fatty acid composition by gas-liquid chromatography). These ISO methods allow for determination of molar concentration of a fatty acid relative to total moles of this fatty acid in TAG ([FA- TAG]).
- the distribution of fatty acids over the glycerol backbone can be determined according to the method disclosed in JOCS/AOCS Official Method Ch 3a- 19 Determination of the composition of fatty acids at the 2-position of oils and fats - Enzymatic Transesterification method using Candida antarctica lipase (Approved 2019) In essence, this method involves hydrolysis of triacylglycerols (TAG) by a sn-1,3 specific pancreatic lipase (porcine).
- TAG triacylglycerols
- the required 2 -monoacylglycerols formed are isolated by thin layer chromatography and these are subsequently methylated for gas chromatographic analysis and quantified in molar concentrations relative to the total moles of fatty acids at the sn-2 position ([FA(sn-2)]).
- GlycA levels were determined using the Nightingale Health platform (https://research.nightingalehealth.com/ under Blood biomarker analysis) as described by Wurtz et al ( P. Wurtz et al Quantitative Serum Nuclear magnetic Resonance metabolomics in Large-Scale Epidemiology: A Primer on -Omics Technologies, Am. J. Epidemiol. 2017 vol 186(9) pp 1084-1096).
- the study population consisted of 40 healthy men and women aged 40-70, with a BMI of 22-27 kg/m 2 . Participants were excluded if they were suffering from any chronic metabolic, gastrointestinal, inflammatory, or another chronic disease, if they had (a history) of gastro-intestinal complaints or surgery, renal or hepatic malfunctioning (determined by ALAT, ASAT, and creatinine measurements), or if they were using any medication that may influence the study results by affecting intestinal motility. Additionally, participants were excluded if they were (wishing to become) pregnant, using soft/hard drugs, drank >14 alcohol consumptions/week, smoked, or had an unstable body weight. Lastly, participants were also excluded from the study if they were following a vegan diet or had food allergies to any of the products used in the study. All participants provided their written consent before participation in the study.
- the study was a double-blind, randomized acute intervention study (Figure la). Each participant visited the research unit three times, with a wash-out period of at least one week. During each study visit, the participants underwent a dietary lipid challenge test in the form of a high-fat shake. Participants were randomly assigned to a sequence of shakes.
- Amounts per 618 gram of shake consisting of water, skimmed milk, and fat shake powder.
- the shakes were prepared by dissolving the fat blend in 500 ml of skimmed milk.
- VEGE vegetable fat blend
- AMF anhydrous milk fat
- CREAM 100% cream
- the shakes were isocaloric and differed solely in their fat source, as the remaining constituents were identical.
- the fats were provided by FrieslandCampina in powder form (Table 2).
- the shakes were prepared by dissolving the fat powders in skimmed milk.
- Vegetable blend Vegetable fat blend (blend of palm olein, rapeseed oil (VEGE) low in erucic acid, palm kernel oil and sunflower oil), glucose syrup, milk protein (Na-caseinate), stabilizer (E451i: Pentasodium triphosphate), free-flowing agent (E551: silicon dioxide) Fat powder Ingredients
- Anhydrous milk fat Anhydrous milk fat, glucose syrup, milk protein (Na- (AMF) caseinate), stabilizer (E451i: Pentasodium triphosphate), free-flowing agent (E551: silicon dioxide) CREAM Cream, milk protein (Na-caseinate), glucose syrup,
- the shakes were provided to the participants in a tinted cup with an opaque straw to hide their content. Participants had to consume the shake within ten minutes and were not allowed to eat or drink anything except for water (ad libitum) unless the last blood sample was drawn. During that time frame, participants were also not allowed to engage in physical exercise.
- alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), body mass index (BMI), hemoglobin (Hb), waist-hip ratio (WHR)
- AZA aspartate aminotransferase
- BMI body mass index
- Hb hemoglobin
- WHR waist-hip ratio
- AMF, CREAM and VEGE impact postprandial metabolites differently
- GlycA is a biomarker of systematic inflammation and has been identified with many metabolic disorders and diseases.
- the postprandial response of GlycA differed significantly between the three shakes. Specifically, CREAM and AMF consumption resulted in a lower GlycA level 6 hours post prandially compared to VEGE. CREAM and AMF consumption resulted in a rapid return of the postprandial increase of GlycA to its basal level, which did not occur after VEGE consumption ( Figure 2a).
- SPC Milk serum protein concentrates
- a nutritional composition e.g. an adult nutrition product
- Ingredients Water, milk protein (SPC), glucose syrup, vegetable oils, (sunflower oil, rapeseed oil), milk fat, sucrose, fiber (fructooligosaccharides, inulin, galactooligosaccharides), minerals, fish oil, emulsifier, vitamins, carnitine, stabilizer, flavor, taurine.
- composition comprises per serving size of 100.0ml:
- Alpha Linolenic Acid 150 - 200 mg
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Pediatric Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dairy Products (AREA)
Abstract
Use of dairy lipid to lower the GlycA level in a subject.
Description
Title: Dairy lipid for lowering the Glycoprotein acetyls (GlycA)
FIELD OF THE INVENTION
The invention disclosed herein relates to the use of dairy lipid to lower the GlycA level in a subject; to a composition comprising a lipid fraction for use in lowering the GlycA level in a subject. The invention further relates to a method for lowering the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject. Optionally the use, composition for use and the method additionally relate to reducing the risk of inflammation in a subject.
BACKGROUND
Breast feeding is the best way to ensure healthy growth and development of infants during the first months of life. It is recommended by the WHO to exclusively provide breast feeding during the first six months of life and the introduction of safe and appropriate complementary feeding thereafter to supplement continued breast feeding up to two years of age or beyond. However, when mothers cannot or choose not to breastfeed for whatever reason a safe alternative to breast feeding is required, there is a legitimate role for breast milk substitutes, produced according to strict international compositional and safety standards.
Glycoprotein acetyls (GlycA) is a unique inflammatory biomarker with analytic and clinical attributes that may complement or provide advantages over existing clinical markers of systemic inflammation. It is composed of a complex of heterogeneous NMR signal containing N-acetyl sugar groups originating from multiple acute-phase circulating glycoproteins. A simplified description how the GlycA ‘peak’ on NMR relates to systemic inflammation is given hereafter: In the setting of inflammation, irrespective of the trigger, macrophages are recruited to the site of inflammation where they secrete a variety of cytokines. These cytokines act locally to induce an inflammatory response aimed at removing the insulting trigger and promoting subsequent tissue recovery. However, some of
these cytokines also enter the systemic circulation and reach the liver, where they induce an increased production and secretion of several so-called acute phase reactants, as well as various glycosylation-mediating enzymes, known as glycosyltransferases, which alter the glycosylation patterns of the latter acute phase reactants. The acute phase reactants themselves, and their glycosyltransferase-modified derivatives contribute to the GlycA peak seen on the NMR spectrum (R.A. Bailout and A.T. Remaley J Lab Precis Med 2020;5:17 I http://dx.doi.org/10.21037/jlpm.2020.03.03). Accordingly, there is a need to keep the level of GlycA low in order to reduce the risk for inflammation.
It was found that eating may result in an increase of the GlycA level. It is desired to have the GlycA levels return to their basal level as fast as possible in order to lower the risk of inflammation or any other condition related to increased levels of GlycA. It was surprisingly found that this so-called postprandial response is dependent on the diet being consumed. More surprisingly, it was found that GlycA returns faster to its basal level after consumption of milk fat as compared to consumption of vegetable fat.
It is an objective of the present invention to provide a further use of milk fat and or milk lipids, to provide a further composition for use and to provide a further method comprising a step of administering milk fat or milk lipids. It is an objective to better address at least one of the aforementioned desires and/or needs.
SUMMARY OF THE INVENTION
One or more objectives of this invention are achieved by the use, composition for use and method as defined in the claims. According to an aspect of the invention this is achieved by the features of claim 1. There is provided a use of dairy lipid to reduce the risk of inflammation in a subject and/or to lower the GlycA level in a subject; preferably, to lower the postprandial GlycA level in a subject. In addition and/or alternatively, according to a further aspect of the invention there is provided a composition comprising a lipid fraction for use in the reduction of the
risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10 wt%.
According to a further aspect of the invention there is provided a method for reducing the risk of inflammation in a subject and/or to lower the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10 wt%.
DETAILED DESCRIPTION OF THE INVENTION
In a first aspect the invention relates to the use of a lipid fraction to lower the Glycoprotein acetyls (GlycA) level in a subject wherein the amount of C 15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
In one embodiment the invention relates to the use of a lipid fraction to reduce the risk of inflammation in a subject and/or to lower the GlycA level in a subject wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%. In one embodiment the invention relates to the use of a lipid fraction to reduce the risk of inflammation in a subject and/or to lower the GlycA level in a subject wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy
lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
As referred to in different embodiments and aspects of the invention, the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids preferably is at least 0.20% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.12%; more preferably the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.30% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.18%. As used herein, the amount of C15:0 in the lipid fraction is referring to amount of pentadecanoic acid that is esterified to the glycerol backbone, likewise, the amount of Cl 7:0 is referring to the amount of heptadecanoic acid that is esterified to the glycerol backbone.
The term "treatment", in relation to a given disease or disorder, includes, but is not limited to, inhibiting the disease or disorder, for example, arresting the development of the disease or disorder; relieving the disease or disorder, for example, causing regression of the disease or disorder; or relieving a condition caused by or resulting from the disease or disorder, for example, relieving, preventing or treating symptoms of the disease or disorder.
The term "prevention" in relation to a given disease or disorder means preventing the onset of disease development if none had occurred, preventing the disease or disorder from occurring in a subject that may be predisposed to the disorder or disease but has not yet been diagnosed as having the disorder or disease, and/or preventing further disease/disorder development if already present.
A reduction of the risk of a disease or disorder means a lower likelihood that a given disease or disorder develops if none had occurred, and/or a lower likelihood that a given disease or disorder further develops if already present, and/or a lower likelihood that a given disease or disorder will be diagnosed.
As used herein, “dairy lipid” consists of dairy fat (i.e. milk fat) and dairy phospholipids (i.e. milk phospholipids). As such the total lipid fraction consists of dairy fat, vegetable fat, dairy phospholipid and vegetable phospholipid. The
“dairy lipid” as used in this document may be obtained from milk of ruminants using methods known in the art, preferably from bovine milk fat, more preferably cow’s milk fat. The milk fat source can in principle be any available ruminant milk fat source, such as whole milk, cream, anhydrous milk fat (AMF) or milk fat fractions resulting from dry fractionation, critical CO2 extraction or other fractionation methods known in the art. The dairy lipid source can also be a source of milk fat globular membrane (MFGM). Likewise, the dairy lipid source can be a combination of different sources. It was, however, found particularly suitable to use whole milk, AMF, cream and/or MFGM as the dairy lipid source. Preferably the ruminant milk lipids are bovine milk lipids and the lipids are selected from the group consisting of anhydrous milk fat (AMF), cream, MFGM, and whole milk. More preferably, the lipids are selected from AMF, cream, or mixtures thereof. Even more preferably, the bovine milk lipids are cow milk lipids. In one embodiment the dairy lipid is bovine whole milk or cream. In one embodiment, the dairy lipid is bovine whole milk, in another embodiment the dairy lipid is bovine cream, in still another embodiment the dairy lipid is bovine AMF. Preferably, the dairy lipid source is bovine AMF and/or bovine MFGM. As used herein, MFGM is referring to an MFGM enriched milk fraction. AMF and MFGM enriched milk fractions are readily commercially available from milk processing companies like FrieslandCampina, Aria, or Fonterra e.g. VMF100 (FrieslandCampina), Vivinal® MFGM (FrieslandCampina), Lacprodan® MFGM- 10 (Aria), SureStart™ MFGM Lipids (NZMP). Conventional techniques can be applied to produce different milk lipid sources like whole milk, cream, anhydrous milk fat (AMF) or milk fat fractions resulting from dry fractionation, critical CO2 extraction or other fractionation methods. Such milk lipid sources are also readily commercially available. If a thermization or pasteurization step is needed e.g. to meet legal requirements, this is possible using methods known in the art, for example at temperatures of about 63 °C (145 °F) maintained for 30 minutes or, heating to a higher temperature, e.g. 72 °C (162 °F), and holding for 15 seconds or, alternatively, e.g. an ultra-high temperature (UHT) treatment at not less than 135 °C in combination with a suitable holding time. Alternatively, the ruminant milk lipids may be obtained from fresh milk.
The term “cream” as used herein is referring to the fat portion from whole milk, preferably bovine milk. This fat portion may be separated from the whole milk using methods known in the art. Cream is comprising triglycerides and milk fat globular membrane (MFGM) fragments (such fragments may also be referred to as MFGM components). The MFGM fragments comprise milk phospholipids and a large variety of (glyco)proteins. The milk fat globules comprise triglycerides surrounded with a membrane comprised of MFGM fragments.
As used herein “postprandial lipemia” refers to a rise in circulating triglyceride- containing lipoproteins following consumption of a meal, postprandial lipemia has been recognized as a risk factor for the development of cardiovascular disease and other chronic diseases.
The term "subject" as used herein preferably refers to a human. The term "subject" refers to both the male and female sex unless one sex is specifically indicated. The human subject can be an infant (< 2 years old), a juvenile, an adolescent, an adult or an elderly subject. In one preferred embodiment the human subject is aged 0-36 months. In a particularly preferred embodiment of the invention the human subject is aged 18 years and above, e.g. at least 25 years, at least 30 years, at least 35 years, at least 40 years, or at least 45 years. More preferably, the human subject is at least 50 years old, at least 55 years old, at least 60 years old or at least 65 years of age. There is no particular upper limit although in practice, human subjects treated in accordance with the invention will typically be at most 110 years of age, e.g. at most 100 or at most 90 years of age.
As is shown in the examples, human consumption of fat results in an increase of the GlycA level. The increase being determined relative to the basal level. The basal level being the GlycA level in the subject in a fasted state of at least 10 hours. During the fasting state, the subject is not allowed to eat or drink, except water. As such, the lowering of the GlycA level as referred to in the different aspects and/or embodiments of the invention is a reduction of the postprandial time needed for the GlycA level to start decreasing, preferably a reduction of the postprandial time needed for the GlycA level to return to its basal level in the
subject after consumption of a composition comprising a lipid fraction. As used herein, “postprandial time” is defined as the time after consumption of a consumption comprising a lipid fraction. Preferably, the lipid fraction in the composition comprising a lipid fraction as referred to in the different aspects and/or embodiments of the invention, comprises at least 10 wt% dairy lipid as determined to the total weight of lipid in the lipid fraction.
Alternatively, in other embodiments of the different aspects of the invention, the lowering of the GlycA level is one or more selected from the group consisting of i.
- v: i. a reduction in the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction as compared to the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of the same amount of vegetable oils is reduced with at least 5%, preferably at least 10%, more preferably at least 15% most preferably at least 20%; and/or ii. a decrease in the GlycA level in the subject between 5 and 6 hours post prandial, preferably between 4 and 6 hours post prandial, most preferably between 3 and 6 hours post prandial; and/or iii. the GlycA level being back at the basal level at 6 hours post prandial; and/or iv the GlycA level at 4.5 hours post prandial being at 60% or less of the GlycA level at 3 hours post prandial, preferably 50% or less; and /or v. the Area Under the Curve (AUG) of the delta postprandial response GlycA being reduced by at least 10%, preferably at least 20%.
As used herein, the Area Under the Curve (AUG) of the delta GlycA postprandial response is referring to a curve like Figure 2, wherein the postprandial GlycA level subtracted with the basal GlycA level is plotted as a function of time between t=0 (basal level) and t=6 hours.
The amount of dairy lipid as determined relative to the total weight of the lipid fraction in the composition comprising a lipid fraction as referred to in different embodiments and/or aspects of the current invention can be at least 20 wt%, preferably at least 30 wt%, more preferably at least 50 wt%, particularly
preferably at least 75 wt%, most preferably at least 90wt%, such as at least 95 wt% or 99 wt%.
The reduced risk of inflammation and/or the lowering of the GlycA level is preferably determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid. More preferably, the vegetable oils consist of a blend of palm olein oil, rapeseed oil low in erucic acid, palm kernel oil and sunflower oil.
The composition comprising a lipid fraction as referred to in different embodiments of the invention may be further comprising a carbohydrate fraction and a protein fraction; preferably wherein the composition comprising the lipid fraction is selected from the group consisting of infant nutrition product, adult nutrition product, a sports nutrition product, drink, candy, and a food supplement. Such products are well-known in the art and the amount of dairy lipid may be increased in such products by replacing other sources of lipid, using methods known in the art.
In another aspect, the invention relates to a composition comprising a lipid fraction for use in lowering the GlycA level in a subject; wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
In one embodiment the invention relates to a composition comprising a lipid fraction for use in the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as
determined relative to the total weight of the lipid fraction is at least 10% wt%. In one embodiment, the invention relates to a composition comprising a lipid fraction for use in the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of Cl 7:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%. Preferably, wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
In some jurisdictions the invention may also be worded as the use of a composition comprising a lipid fraction in the manufacture of a medicament for use in lowering the GlycA level in a subject; wherein the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of Cl 7:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
In one embodiment the invention relates to the use of such a composition comprising a lipid fraction in the manufacture of a medicament for use in the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%. In one embodiment, the invention relates to a use of a composition comprising a lipid fraction for use in the manufacture of a medicament for the reduction of the risk of inflammation in a subject and/or to lower the GlycA level in a subject; wherein the amount of
C15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%. Preferably, wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
In yet another aspect, the invention relates to a method for lowering the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the lowering of the GLycA level is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%.
In one embodiment the invention relates to a method for reducing the risk of inflammation in a subject and/or to lower the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%. In one embodiment, the invention relates to a method for reducing the risk of inflammation in a subject and/or to lower the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and wherein the amount of dairy lipid
as determined relative to the total weight of the lipid fraction is at least 10% wt%. Preferably, wherein the lowering of the GlycA level is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
In one embodiment, the use, composition for use, and method of the invention as defined in the different aspects and embodiments of the invention relate to a reduction in the risk of inflammation in a subject and a lowering of the GlycA level in a subject.
In one embodiment the invention relates to the use, the composition for use, or the method of the invention wherein the GlycA level is lowered and wherein the risk of inflammation is reduced; preferably wherein the reduced risk of inflammation is determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid.
It is also to be understood that this invention is not limited to the specific embodiments and methods described herein, as specific components and/or conditions may, of course, vary. Furthermore, the terminology used herein is used only for the purpose of describing particular embodiments of the present invention and is not intended to be limiting in any way.
It must also be noted that, as used in the specification and the appended claims, the singular form "a", "an," and "the" comprise plural referents unless the context clearly indicates otherwise. For example, reference to a component in the singular is intended to comprise a plurality of components.
It will be understood that within this disclosure, any reference to a weight, weight ratio, and the like pertains to the dry matter, in particular the dry matter of the composition.
Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
As used herein, the term "comprising", which is synonymous with "including" or "containing", is open-ended, and does not exclude additional, unrecited element(s), ingredient(s) or method step(s), whereas the term "consisting of' is a closed term, which excludes any additional element, step, or ingredient which is not exphcitly recited.
As used herein, the term “essentially consisting of’ is a partially open term, which does not exclude additional, unrecited element(s), step(s), or in gre dient (s), as long as these additional element(s), step(s) or ingredient(s) do not materially affect the basic and novel properties of the invention.
As used herein, the term “comprising” (or “comprise(s)”) hence includes the term “consisting of’ (“consist(s) of’), as well as the term “essentially consisting of’ (“essentially consist(s) of’). Accordingly, the term “comprising” (or “comprise(s)”) is, in the present application, meant as more particularly encompassing the term “consisting of’ (“consist(s) of’), and the term “essentially consisting of’ (“essentially consist(s) of’).
Throughout this application, where publications are referenced, the disclosures of these publications in their entireties are hereby incorporated by reference into this application to more fully describe the state of the art to which this invention pertains.
Except in the examples, or where otherwise expressly indicated, all numerical quantities in this description indicating amounts of material or conditions of reaction and/or use are to be understood as modified by the word "about" in describing the broadest scope of the invention. Practice within the numerical limits stated is generally preferred. Also, unless expressly stated to the contrary: percent, "parts of," and ratio values are by weight; the description of a group or class of materials as suitable or preferred for a given purpose in connection with the invention implies that mixtures of any two or more of the members of the group or class are equally suitable or preferred; description of constituents in chemical terms refers to the constituents at the time of addition to any combination specified in the description, and does not necessarily preclude chemical interactions among the constituents of a mixture once mixed; the first definition of an acronym or other abbreviation applies to all subsequent uses
herein of the same abbreviation and applies, mutatis mutandis, to normal grammatical variations of the initially defined abbreviation; and, unless expressly stated to the contrary, measurement of a property is determined by the same technique as previously or later referenced for the same property.
The invention is hereinafter illustrated with reference to the following, nonlimiting, examples.
DETAILED DESCRIPTION OF THE FIGURES
Figure 1 Differential effects of interventions on postprandial metabolites. Flowchart of A) the study design and B) the number of metabolites significantly changed in the interventions. Shake*time effect was tested using linear mixed models for repeated measures. Significant findings were corrected for multiple testing using FDR-correction (FDR p-value<0.05). A LSD posthoc test was performed on metabolites with a significant FDR p-value for shake*time to identify differences between the shakes and shake*time effects at specific time points.
Figure 2 Delta postprandial response of GlycA. Delta postprandial response of glycoprotein acetyls (GlycA). All values represent mean ± SD. Shake*time effect in linear mixed models analysis (FDR p-value = 0.019). Significant difference between VEGE and AMF (p<0.001). and VEGE and CREAM (p=0.003). a and b indicate significant differences between shakes for shake*time effect at specific timepoints. All values represent mean ± SD.
EXAMPLES
Example 1
Fatty acid determination
[0068]The content of the different fatty acids in the lipid of the composition of the invention can be determined by standard method ISO 15884/IDF 182:2002 (Milk fat - Preparation of fatty acid methyl esters) and ISO 15885/IDF 184 (Milk fat - Determination of the fatty acid composition by gas-liquid chromatography). These ISO methods allow for determination of molar concentration of a fatty acid
relative to total moles of this fatty acid in TAG ([FA- TAG]). The distribution of fatty acids over the glycerol backbone can be determined according to the method disclosed in JOCS/AOCS Official Method Ch 3a- 19 Determination of the composition of fatty acids at the 2-position of oils and fats - Enzymatic Transesterification method using Candida antarctica lipase (Approved 2019) In essence, this method involves hydrolysis of triacylglycerols (TAG) by a sn-1,3 specific pancreatic lipase (porcine). The required 2 -monoacylglycerols formed are isolated by thin layer chromatography and these are subsequently methylated for gas chromatographic analysis and quantified in molar concentrations relative to the total moles of fatty acids at the sn-2 position ([FA(sn-2)]).
Determination of the GlycA level in a subject
GlycA levels were determined using the Nightingale Health platform (https://research.nightingalehealth.com/ under Blood biomarker analysis) as described by Wurtz et al ( P. Wurtz et al Quantitative Serum Nuclear magnetic Resonance metabolomics in Large-Scale Epidemiology: A Primer on -Omics Technologies, Am. J. Epidemiol. 2017 vol 186(9) pp 1084-1096). Briefly, using a A high-throughput proton (1H) nuclear magnetic resonance (NMR) metabonomics approach as described by Soininen et al (Soininen et al High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism; Analyst, 2009, vol 134, pp 1781-1785).
Clinical study
A study was performed aimed to explore the postprandial response of plasma metabolites to high fat shake consumptions, including vegetable fats and bovine milk fats with and without milk fat globular membranes.
Study population
The study population consisted of 40 healthy men and women aged 40-70, with a BMI of 22-27 kg/m2. Participants were excluded if they were suffering from any chronic metabolic, gastrointestinal, inflammatory, or another chronic disease, if they had (a history) of gastro-intestinal complaints or surgery, renal or hepatic
malfunctioning (determined by ALAT, ASAT, and creatinine measurements), or if they were using any medication that may influence the study results by affecting intestinal motility. Additionally, participants were excluded if they were (wishing to become) pregnant, using soft/hard drugs, drank >14 alcohol consumptions/week, smoked, or had an unstable body weight. Lastly, participants were also excluded from the study if they were following a vegan diet or had food allergies to any of the products used in the study. All participants provided their written consent before participation in the study.
Study Design
The study was a double-blind, randomized acute intervention study (Figure la). Each participant visited the research unit three times, with a wash-out period of at least one week. During each study visit, the participants underwent a dietary lipid challenge test in the form of a high-fat shake. Participants were randomly assigned to a sequence of shakes.
The evening before each study visit, participants consumed a standardized meal (ad libitum) and were not allowed to eat or drink anything except water until the next day. The following day, participants appeared at the research unit in a fasted state for a minimum of 10 hours.
The study was conducted at Wageningen University, the Netherlands, from 07- 01-2020 until 10-03-2020. The experimental protocol and procedures were approved by the Medical Ethical Committee of Wageningen University and were in accordance with the Helsinki declaration of 1975 as revised in 1983. The study was registered at clinicaltrials.gov as NCT04178681 ‘Postprandial Effects of Milk Fats (POEMI)’.
Dietary lipid challenge test
During each study visit, participants underwent a dietary lipid challenge test. In this test, participants consumed a liquid shake containing skimmed milk (0.5 L) and 95 grams of fat from different sources (Table 1).
Table 1. Nutritional information on the high-fat shakes
Amounts per 618 gram of shake (consisting of water, skimmed milk, and fat shake powder.
Constituent VEGE AMF Cream
Fat
Vegetable fat blend 95.0 0 0 (g)
Anhydrous Milk Fat (AMF) 0 95.0 0 (g)
Cream 0 0 95.0 (g)
Fat (total) * 95.5 95.5 95.5 (g)
Protein 20.9 20.9 21.2 (g)
Carbohydrate 42.3 42.3 42.5 (g)
0.5 g of fat via skimmed milk
The shakes were prepared by dissolving the fat blend in 500 ml of skimmed milk.
Three types of fat were consumed during this study, namely: 100% vegetable fat blend (VEGE), 100% anhydrous milk fat (AMF, bovine milk fat), and 100% cream (CREAM) (AMF + milk fat globular membranes). The shakes were isocaloric and differed solely in their fat source, as the remaining constituents were identical. The fats were provided by FrieslandCampina in powder form (Table 2). The shakes were prepared by dissolving the fat powders in skimmed milk.
Table 2. The ingredient list of the three different fat powders
Fat powder Ingredients
Vegetable blend Vegetable fat blend (blend of palm olein, rapeseed oil (VEGE) low in erucic acid, palm kernel oil and sunflower oil), glucose syrup, milk protein (Na-caseinate), stabilizer (E451i: Pentasodium triphosphate), free-flowing agent (E551: silicon dioxide)
Fat powder Ingredients
Anhydrous milk fat Anhydrous milk fat, glucose syrup, milk protein (Na- (AMF) caseinate), stabilizer (E451i: Pentasodium triphosphate), free-flowing agent (E551: silicon dioxide) CREAM Cream, milk protein (Na-caseinate), glucose syrup,
(AMF+MFGM) stabilizer (E451i: Pentasodium triphosphate), free- flowing agent (E551: silicon dioxide)
Fatty acid composition of the lipid blend
The fatty acid composition of the different fat blends as given in Table 3, was determined using the method described elsewhere in this example. The amounts listed are expressed as percent by weight of the total amount of fatty acids (w/w%) in the lipid fraction.
Table 3 Fatty acid composition of the different fat shakes
Fatty acid (w/w%)* VEGE AMF Cream
C15:0 <0.1 1.1 1.1
C17:0 <0.1 0.5 0.5
* amounts listed are expressed as percent by weight of the total amount of fatty acids (w/w%) in the lipid fraction.
The shakes were provided to the participants in a tinted cup with an opaque straw to hide their content. Participants had to consume the shake within ten minutes and were not allowed to eat or drink anything except for water (ad libitum) unless the last blood sample was drawn. During that time frame, participants were also not allowed to engage in physical exercise.
Blood collection
During each study visit, a catheter cannula was inserted in the participant’s antecubital vein. Thirty minutes after the cannula insertion, blood was drawn from the catheter cannula for the baseline measurement (t=0). After this baseline measurement, participants consumed a high-fat shake. Subsequently, blood was
drawn at t=l, 2, 3, 4, 5, 6, 7, and 8 hours after consumption. All blood samples were stored at -80°C until further analysis.
Metabolomics
Blood samples collected at 0 hours (baseline), 3 hours, and 6 hours were processed by Nightingale Health. This platform performs high-throughput proton Nuclear Magnetic Resonance (NMR). Details on the analysis have been described previously (Soininen, P., Kangas, A. J., Wurtz, P., Suna, T., and Ala-Korpela, M. (2015). Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ. Cardiovasc. Genet. 8, 192-206; Wurtz, P., Kangas, A. J., Soininen, P., Lawlor, D.A., Davey Smith, G., and Ala- Korpela, M. (2017). Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies.
Am. J. Epidemiol. 186, 1084-1096); Soininen et al High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism; Analyst, 2009, vol 134, pp 1781-1785). The analysis allows for simultaneous detection and quantification of 249 metabolites and their corresponding ratios within one experimental set-up. These include lipoprotein subclasses and constituents, their relative ratios, lipids, fatty acids, amino acids, ketone bodies, glycolysis-related metabolites, and various other low-molecular-weight metabolites.
Statistical analysis
Statistical analyses of the metabolites were performed on log2-transformed data. Differences in the postprandial responses between the three different shakes from the dietary lipid challenge test were analyzed using linear mixed models for repeated measures. Participants were specified as subjects. Shake and time were specified as repeated measures. The delta values (t=3h-t=0h and t=6h-t=0h) of the 249 metabolites were selected as the dependent variable in the model. Shake, time, and the interaction between shake*time were included as fixed effects. A first-order autoregressive covariance structure was selected for the model. An additional LSD posthoc test was performed on metabolites with a significant shake*time effect to identify differences between the shakes and specify
shake*time effects at specific time points. The linear mixed model’s findings were corrected for multiple testing using Benjamini-Hochberg’s FDR correction (FDR p-value 0.05) ([ Benjamini, Y. and Hochberg, Y. (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J. R. Stat. Soc. Ser. B 57, 289-300). All statistical analyses were performed using IBM® SPSS® Statistics (version 28.0.1.0). Figures were created in GraphPad Prism (Version 9.3.1) and Cytoscape (version 3.9.1).
Results Participant characteristics
Of the 40 participants that entered this study, 37 completed the study. One participant dropped out after the first study visit, and two other participants dropped out after the second study visit (Figure 1A). Data from the dropouts were still included in the analysis. The participant characteristics of the 40 participants can be found in Table 4.
Table 4. Participant characteristics of the 40 included participants
Data are presented as mean ± standard deviation.
Characteristic
Gender (m/f) 9/31
Age (years) 57.3 ± 8.0
Weight (kg) 71.5 ± 8.5
Height (cm) 172.2 ± 7.7
BMI (kg/m2) 24.1 ± 1.7
Waist circumference (cm)
Men 92.2 ± 5.9
Women 81.8 ± 6.2
Hip circumference (cm)
Men 102.6 ± 4.6
Women 102.2 ± 6.0
WH R
Men 0.90 ± 0.05
Characteristic
Women 0.80 ± 0.05
Hb (mmol/L) 8.4 ± 0.6
ALAT (uL) 24.7 ± 11.8
ASAT (uL) 21.5 ± 7.3
Creatinine (umol/L) 71.6 ± 11.1
Abbreviations: alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), body mass index (BMI), hemoglobin (Hb), waist-hip ratio (WHR)
AMF, CREAM and VEGE impact postprandial metabolites differently
The effect of the 3 fat sources on postprandial plasma metabolite levels (between shake comparison) was investigated. Of the 249 metabolites measured in total, 102 metabolites were differently changed postprandially by the three shakes. Posthoc tests were performed to identify the differences between shakes at a specific time point. At 3 hours postprandially, 37 metabolites were significantly different between VEGE and AMF, 39 metabolites were significantly different between VEGE and CREAM, and no metabolites were significantly different between AMF and CREAM. At 6 hours postprandially, 41, 29, and 8 metabolites were identified as significantly different for the above comparisons, respectively (Figure lb).
Significant changes of metabolites in between-shake comparisons and within- shake comparisons
Differences between the three shakes were tested using linear mixed models for repeated measures. A significant shake*time effect was found for 102 of the 239 metabolites. Significant findings were corrected for multiple testing using FDR- correction (FDR p-value<0.05). Additional LSD posthoc tests were performed to identify the differences between shakes and shake*time effects at a specific timepoint (Figure lb).
AMF and CREAM consumption led to a more rapid decline in the postprandial increase of the inflammatory marker GlycA
GlycA is a biomarker of systematic inflammation and has been identified with many metabolic disorders and diseases. Surprisingly, the postprandial response of GlycA differed significantly between the three shakes. Specifically, CREAM and AMF consumption resulted in a lower GlycA level 6 hours post prandially compared to VEGE. CREAM and AMF consumption resulted in a rapid return of the postprandial increase of GlycA to its basal level, which did not occur after VEGE consumption (Figure 2a). As used herein, the “GlycA level” is referring to the delta values of the measured GlycA level at a specific postprandial time point and the GlycA level at baseline (t=3h-t=0h and t=6h-t=0h). CREAM and AMF have their highest GlycA level 3 hours postprandially, while VEGE increases up to 6 hours postprandially. It is further noted that at t=6, the GlycA level has returned to baseline level for both CREAM and AMF.
It is observed that the postprandial increase of low-grade chronic inflammation marker glycoprotein acetyls (GlycA) was lower and almost back to baseline, 6 hours postprandial after CREAM and AMF consumption while VEGE still seems to rise.
Example 2
An example of a nutritional composition (e.g. an infant formula) suitable to be used in different embodiments or aspects of the invention is given in the below table 5.
* Milk serum protein concentrates (SPC) are proteins found in cheese whey that are removed directly from milk. Because SPC are not exposed to the cheesemaking process, enzymatic or chemical reactions that can lead to off-flavors are reduced.
Example 3
An example of a nutritional composition (e.g. an adult nutrition product) suitable to be used in different embodiments or aspects of the invention is given below: Ingredients: Water, milk protein (SPC), glucose syrup, vegetable oils, (sunflower oil, rapeseed oil), milk fat, sucrose, fiber (fructooligosaccharides, inulin, galactooligosaccharides), minerals, fish oil, emulsifier, vitamins, carnitine, stabilizer, flavor, taurine.
The composition comprises per serving size of 100.0ml:
Energy: 550 - 800 kJ
Protein: 5 - 15 g (from SPC)
Dietary Fiber: 1 - 5 g
Fat: 5 - 10 g
Carbohydrate: 10 - 15 g
Alpha Linolenic Acid: 150 - 200 mg,
Calcium: 200 - 350 mg
Poly Un Saturated Fat: 3 - 5 g.
Claims
Claims Use of a lipid fraction to lower the Glycoprotein acetyls (GlycA) level in a subject wherein the amount of C 15:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%; ; and wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction. The use of claim 1 wherein the lipid fraction comprises at least 10 wt% dairy lipid as determined to the total weight of lipid in the lipid fraction. The use of any of the preceding claims wherein the lowering of the GlycA level is determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid. A composition comprising a lipid fraction for use in lowering the GlycA level in a subject; wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of C17:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt%; and wherein the lowering of GlycA is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction.
The composition for use of claim 4 wherein the lowering of the GlycA level is determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid. Method for lowering the GlycA level in a subject comprising a step of administering a composition comprising a lipid fraction to the subject, wherein the amount of 015:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.10% and the amount of 017:0 in the lipid fraction expressed as percent by weight of total fatty acids is at least 0.06%; and optionally wherein the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 10% wt% ; and wherein the lowering of the GLycA level is a reduction of the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction. The method of claim 6 wherein the lowering of the GlycA level is determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid. The use, or the composition for use, or the method of any of the preceding claims wherein the composition comprises a lipid fraction and the amount of dairy lipid as determined relative to the total weight of the lipid fraction is at least 20 wt%, preferably at least 30 wt%, more preferably at least 50 wt%, particularly preferably at least 75 wt%, most preferably at least 90wt%, such as at least 95 wt% or 99 wt%. The use, or the composition for use, or the method of any of the preceding claims wherein the dairy lipid is selected from one or more of the group consisting of anhydrous milk fat (AMF), cream, MFGM and whole milk;
preferably wherein the dairy lipid is selected from AMF, cream or mixtures thereof. The use, or the composition for use, or the method of the preceding claims wherein the subject is a human subject, preferably a human subject aged 0 to 36 months, particularly preferably a human subject aged 18 years and above, more preferably a human subject aged 50 years and above. The use, or the composition for use, or the method of the preceding claims wherein the composition comprising the lipid fraction is further comprising a carbohydrate fraction and a protein fraction; preferably wherein the composition comprising the lipid fraction is selected from the group consisting of infant nutrition product, adult nutrition product, a sports nutrition product, drink, candy, and a food supplement. The use, or the composition for use, or the method of the preceding claims wherein i. the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of a composition comprising a lipid fraction as compared to the postprandial time needed for the GlycA level to return to its basal level in the subject after consumption of the same amount of vegetable oils is reduced with at least 5%, preferably at least 10%, more preferably at least 15% most preferably at least 20%; and/or ii. the GlycA level is decreasing in the subject between 5 and 6 hours post prandial, preferably between 4 and 6 hours post prandial, most preferably between 3 and 6 hours post prandial. The use, or the composition for use, or the method of the preceding claims wherein iii. the GlycA level is back at the basal level at 6 hours post prandial; and/or
iv. the GlycA level at 4.5 hours postprandial is at 60% or less of the GlycA level at 3 hours post prandial. The use, or the composition for use, or the method of the preceding claims wherein v. the Area Under the Curve (AUG) of the delta postprandial response GlycA being reduced by at least 10%, preferably at least 20%. The use, or the composition for use, or the method of the preceding claims wherein the GlycA level is lowered and wherein the risk of inflammation is reduced; preferably wherein the reduced risk of inflammation is determined relative to the subject consuming a composition comprising a lipid fraction wherein the lipid fraction consist of vegetable oils instead of dairy lipid.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22204467.9 | 2022-10-28 | ||
EP22204467 | 2022-10-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024089179A1 true WO2024089179A1 (en) | 2024-05-02 |
Family
ID=84364145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/079941 WO2024089179A1 (en) | 2022-10-28 | 2023-10-26 | Dairy lipid for lowering the glycoprotein acetyls (glyca) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024089179A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140105875A1 (en) * | 2011-06-08 | 2014-04-17 | Nestec S.A. | Nutritional compositions having exogenous milk fat globule membrane components |
US20180185316A1 (en) * | 2016-12-29 | 2018-07-05 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and Methods for Diagnosis and Treatment of Inflammation |
-
2023
- 2023-10-26 WO PCT/EP2023/079941 patent/WO2024089179A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140105875A1 (en) * | 2011-06-08 | 2014-04-17 | Nestec S.A. | Nutritional compositions having exogenous milk fat globule membrane components |
US20180185316A1 (en) * | 2016-12-29 | 2018-07-05 | The United States Of America As Represented By The Secretary Of The Navy | Compositions and Methods for Diagnosis and Treatment of Inflammation |
Non-Patent Citations (11)
Title |
---|
BENJAMINI, YHOCHBERG, Y: "Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing", J. R. STAT. SOC. SER. B, vol. 57, 1995, pages 289 - 300 |
DEMMER ELIEKE ET AL: "Addition of a dairy fraction rich in milk fat globule membrane to a high-saturated fat meal reduces the postprandial insulinaemic and inflammatory response in overweight and obese adults", JOURNAL OF NUTRITIONAL SCIENCE, vol. 5, 1 January 2016 (2016-01-01), XP055981667, DOI: 10.1017/jns.2015.42 * |
KUMAR M. VIJAYA ET AL: "The anhydrous milk fat, ghee, lowers serum prostaglandins and secretion of leukotrienes by rat peritoneal macrophages", PROSTAGLANDINS, LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 1 October 1999 (1999-10-01), pages 249 - 254, XP093032588, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0952327899900972> [retrieved on 20230317] * |
LORDAN R ET AL: "Invited review:The anti-inflammatory properties of dairy lipids", JOURNAL OF DAIRY SCIENCE, vol. 100, no. 6, 2017, pages 4197 - 4212, XP085024808, ISSN: 0022-0302, DOI: 10.3168/JDS.2016-12224 * |
P. WURTZ ET AL.: "Quantitative Serum Nuclear magnetic Resonance metabolomics in Large-Scale Epidemiology: A Primer on -Omics Technologies", AM. J. EPIDEMIOL., vol. 186, no. 9, 2017, pages 1084 - 1096 |
R.A. BALLOUTA.T. REMALEY, J LAB PRECIS MED, vol. 5, 2020, Retrieved from the Internet <URL:http://dx.doi.org/10.21037/jlpm.2020.03.03> |
SOININEN ET AL.: "High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism", ANALYST, vol. 134, 2009, pages 1781 - 1785 |
SOININEN, P.KANGAS, A.J.WURTZ, P.SUNA, T.ALA-KORPELA, M: "Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics", CIRC. CARDIOVASC. GENET., vol. 8, 2015, pages 192 - 206 |
VENN-WATSON STEPHANIE ET AL: "Efficacy of dietary odd-chain saturated fatty acid pentadecanoic acid parallels broad associated health benefits in humans: could it be essential?", vol. 10, no. 1, 18 May 2020 (2020-05-18), XP093032758, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-020-64960-y> DOI: 10.1038/s41598-020-64960-y * |
WANG HUIFEN ET AL: "Obesity modifies the relations between serum markers of dairy fats and inflammation and oxidative stress among adolescents", vol. 19, no. 12, 30 November 2011 (2011-11-30), pages 2404 - 2410, XP009533025, ISSN: 1930-739X, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1038%2Foby.2011.234> [retrieved on 20120906], DOI: 10.1038/OBY.2011.234 * |
WURTZ, P.KANGAS, A.J.SOININEN, P.LAWLOR, D.A.DAVEY SMITH, G.ALA-KORPELA, M: "Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies", AM. J. EPIDEMIOL., vol. 186, 2017, pages 1084 - 1096 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lauritzen et al. | Fluctuations in human milk long‐chain PUFA levels in relation to dietary fish intake | |
US20230270151A1 (en) | Nutritional composition having lipophilic compounds with improved solubility and bioavailability | |
AU2009200897B2 (en) | Oils enriched with diacylglycerols and phytosterol ester for use in the reduction of cholesterol and triglycerides | |
US20140323574A1 (en) | Infant formula with high sn-2 palmitate and oligofructose | |
Rahmawaty et al. | Stunting is a recognized problem: Evidence for the potential benefits of ω-3 long-chain polyunsaturated fatty acids | |
BRPI0818230B1 (en) | USES OF COMPLEX LIPIDS TO MAINTAIN OR INCREASE THE GROWTH OR COGNITIVE DEVELOPMENT OF A FETUS, INFANT OR CHILD | |
Arsić et al. | Altered plasma and erythrocyte phospholipid fatty acid profile in elite female water polo and football players | |
CN103781370A (en) | Infant nutrition for regulating food intake later in life | |
Luise et al. | Evaluation of breed and parity order effects on the lipid composition of porcine colostrum | |
US20160309769A1 (en) | Synthetic milk compositions comprising polyunsaturated fatty acids (pufas) for promoting the healthy establishment of cognitive function in male and female infant and children | |
Akrami et al. | A comparative study of the effect of flaxseed oil and sunflower oil on the coagulation score, selected oxidative and inflammatory parameters in metabolic syndrome patients | |
EP2068908B1 (en) | A milk protein composition and use thereof | |
Yanni et al. | Daily consumption of fruit-flavored yoghurt enriched with vitamins B contributes to lower energy intake and body weight reduction, in type 2 diabetic patients: a randomized clinical trial | |
Ikeda et al. | Effects of breastfeeding on the risk factors for metabolic syndrome in preterm infants | |
Bayley et al. | Longer term effects of early dietary cholesterol level on synthesis and circulating cholesterol concentrations in human infants | |
CN114745969A (en) | Infant formula with specific lipid structure for improving the postnatal growth of infants born to overweight and obese mothers | |
Nitta et al. | Effects of nutritional supplementation with antioxidant vitamins and minerals and fish oil on antioxidant status and psychosocial stress in smokers: an open trial | |
WO2024089179A1 (en) | Dairy lipid for lowering the glycoprotein acetyls (glyca) | |
WO2024089169A1 (en) | Dairy lipid for reducing bcaa levels and related disorders | |
Shi et al. | Safety evaluation of phytosterols in laying hens: effects on laying performance, clinical blood parameters, and organ development | |
Burdge et al. | Docosahexaenoic acid is selectively enriched in plasma phospholipids during pregnancy in Trinidadian women–results of a pilot study | |
Kojima et al. | The consumption of a structured triacylglycerol containing behenic and oleic acids increases fecal fat excretion in humans | |
US20160296585A1 (en) | Infant nutrition for improvement in insulin sensitivity later in life | |
López | Correlation Between Fatty Acid Profile in Plasma and Mature Breast Milk | |
EP4068991B1 (en) | Infant formula with special lipid architecture for improving postnatal growth of infants born by caesarean section |